Cancer News and Research

Latest Cancer News and Research

Accuray receives shareholders approval to acquire TomoTherapy

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Incorporated by Accuray.

10 Jun 2011

Drugs for enlarged prostate raise cancer risk

According to health officials, this Thursday, a class of drugs meant to improve symptoms of an enlarged prostate gland may actually increase the chance of getting a more serious form of prostate cancer. However they also said the drugs' benefits outweigh the risks.

9 Jun 2011

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

CLC Bio unveils new framework for visualizing, combining and analyzing genome data

Today at the Copenhagenomics conference, CLC bio has revealed Genomics Gateway - a new framework for visualizing, combining and analyzing genome data.

9 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

PDL revises revenue guidance for second quarter 2011 to $122M

PDL BioPharma, Inc. (PDL) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.

9 Jun 2011

National survey finds women more likely to see doctor on regular basis than men

A national survey found that women were three times more likely to see a doctor on a regular basis than men. Even though men on average die younger than women and have higher mortality rates for heart disease, cancer, stroke and AIDS, trying to get a man to a doctor can be harder than pulling teeth. So, why do men hate it so?.

9 Jun 2011

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that Seattle Genetics has exercised an option to co-develop a second antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement.

9 Jun 2011

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

9 Jun 2011

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

The American Society of Clinical Oncology (ASCO) on Monday sent a letter signed by major U.S. medical societies representing about 300,000 health care professionals to the White House urging President Barack Obama to participate in the U.N. High Level Meeting on Noncommunicable Diseases that is scheduled for September, Agence France-Presse reports.

9 Jun 2011

New NCIN report: Poorer women more likely to die from breast cancer

Poorer women from deprived areas are less likely to survive breast cancer as they are diagnosed at a later stage which means the best available treatments won't be as effective according to a new report out today (Thursday) by the National Cancer Intelligence Network (NCIN).

9 Jun 2011

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Rio Tinto Alcan donates $10M to CHUM and MUHC Joint Corporate Campaign

The Fondation du Centre hospitalier de l'Université de Montréal (CHUM) and the McGill University Health Centre Foundation (MUHC) officially announce a significant gift of 10 million dollars donated by Rio Tinto Alcan to their Joint Corporate Campaign.

9 Jun 2011

Article reports on bright future and enormous need for stem cell therapeutics

An article in the current issue of Technology & Innovation, Proceedings of the National Academy of Inventors - reports on the bright future and enormous need for stem cell therapeutics that may offer hope for those suffering from debilitating and deadly diseases.

9 Jun 2011

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRIC has been completed.

9 Jun 2011

Innovative hands-free device can reduce risk of cancer from cell phone radiation

A new report from the World Health Organization (WHO)/Interactional Agency for Research on Cancer (IARC) released last week has revealed another potential health risk for consumers.

9 Jun 2011

Research provides new insights into how cilia are assembled on the cell surface

Body cells detect signals that control their behavior through tiny hairs on the cell surface called cilia. Serious diseases and disorders can result when these cilia do not work properly.

9 Jun 2011

Insight into how cancer cells acquire selective survival advantage

Research led by David Litchfield of The University of Western Ontario has identified how biochemical pathways can be "rewired" in cancer cells to allow these cells to ignore signals that should normally trigger their death. It's one way that cancer cells may become resistant to therapy.

9 Jun 2011